Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Wikimedia Commons
BD, formerly known as Becton, Dickinson & Co., is buying C.R. Bard in a $24 billion deal that would close later this year. The combined medical device company would make and sell heart devices, medication management systems, catheters and other drug-related hospital products, and it would have $16 billion in annual revenue.
The bottom line: This deal comes a couple years after BD bulked up with its $12 billion acquisition of CareFusion. BD and other medical device companies are attempting to offset pricing pressure from consolidating hospitals and health systems through their own mergers — creating an arms race in health care over market power. More of these deals are likely, especially if the resulting medical device company can serve more as a one-stop shop for hospitals.